4.7 Article

N6-isopentenyladenosine and analogs activate the NRF2-mediated antioxidant response

期刊

REDOX BIOLOGY
卷 2, 期 -, 页码 580-589

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.redox.2014.03.001

关键词

Modified nucleosides; Gene expression; Reactive oxygen species; Anti-inflammatory drug; Pathway analysis

资金

  1. Italian Association for Cancer Research (AIRC)
  2. talian Foundation for Cancer Research (FIRC)
  3. International Research of the Italian Ministry for Education, University and Research
  4. Italian Ministry for Education, University and Research t

向作者/读者索取更多资源

N-6-isopentenyladenosine (i(6)A), a naturally occurring modified nucleoside, inhibits the proliferation of human tumor cell lines in vitro, but its mechanism of action remains unclear. Treatment of MCF7 human breast adenocarcinoma cells with i6A or with three synthetic analogs (allyl(6)A, benzyl(6)A, and butyl(6)A) inhibited growth and altered gene expression. About 60% of the genes that were differentially expressed in response to i6A treatment were also modulated by the analogs, and pathway enrichment analysis identified the NRF2-mediated oxidative stress response as being significantly modulated by all four compounds. Luciferase reporter gene assays in transfected MCF7 cells confirmed that i6A activates the transcription factor NRF2. Assays for cellular production of reactive oxygen species indicated that i(6)A and analogs had antioxidant effects, reducing basal levels and inhibiting the H2O2- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced production in MCF7 or dHL-60 (HL-60 cells induced to differentiate along the neutrophilic lineage) cell lines, respectively. In vivo, topical application of i(6)A or benzyl(6)A to mouse ears prior to TPA stimulation lessened the inflammatory response and significantly reduced the number of infiltrating neutrophils. These results suggest that i(6)A and analogs trigger a cellular response against oxidative stress and open the possibility of and benzyl(6)A being used as topical anti-inflammatory drugs. 2014 The Authors. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

Chiara Fallerini, Nicola Picchiotti, Margherita Baldassarri, Kristina Zguro, Sergio Daga, Francesca Fava, Elisa Benetti, Sara Amitrano, Mirella Bruttini, Maria Palmieril, Susanna Croci, Mirjam Lista, Giada Beligni, Floriana Valentino, Ilaria Meloni, Marco Tanfoni, Francesca Minnai, Francesca Colombo, Enrico Cabri, Maddalena Fratelli, Chiara Gabbi, Stefania Mantovani, Elisa Frullanti, Marco Gori, Francis P. Crawley, Guillaume Butler-Laporte, Brent Richards, Hugo Zeberg, Miklos Lipcsey, Michael Hultstrom, Kerstin U. Ludwig, Eva C. Schulte, Erola Pairo-Castineira, John Kenneth Baillie, Axel Schmidt, Robert Frithiof, Francesca Mari, Alessandra Renieri, Simone Furini

Summary: The study developed a machine-learning model using common and rare exonic variants to predict COVID-19 severity. By selecting key Boolean features and combining them into an Integrated PolyGenic Score, the model offers insights into the genetic contribution to disease severity. A quarter of the selected genes are sex-specific, and pathway analysis highlighted the multi-organ nature of COVID-19 severity. This model could potentially aid in diagnostics, therapeutics, and disease management at the bedside.

HUMAN GENETICS (2022)

Article Oncology

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

Sara Pizzamiglio, Giulia Cosentino, Chiara M. Ciniselli, Loris De Cecco, Alessandra Cataldo, Ilaria Plantamura, Tiziana Triulzi, Sarra El-abed, Yingbo Wang, Mohammed Bajji, Paolo Nuciforo, Jens Huober, Susan L. Ellard, David L. Rimm, Andrea Gombos, Maria Grazia Daidone, Paolo Verderio, Elda Tagliabue, Serena Di Cosimo, Marilena V. Iorio

Summary: The study evaluated the predictive and prognostic value of basal primary tumor miRNA expression profile in trastuzumab treatment and identified miRNA signatures associated with clinical outcomes. These miRNA markers have the potential to be a useful tool in identifying patients with differential responses to trastuzumab-based neoadjuvant therapy.

CANCER MEDICINE (2022)

Article Oncology

A homogeneous treatment for non-DIPG diffuse midline glioma

Elisabetta Schiavello, Veronica Biassoni, Giovanna Gattuso, Marta Podda, Stefano Chiaravalli, Francesco Barretta, Manila Antonelli, Loris De Cecco, Emilia Pecori, Lorenza Gandola, Maura Massimino

Summary: This is a small series of homogeneously-treated DMG patients with H3K27M mutation. The treatment approach is similar to DIPG and the results obtained are comparable with those of DIPG patients. Therefore, these DMG patients should be included in registries and protocols of DIPG.

TUMORI JOURNAL (2023)

Article Oncology

Genetic predisposition to lung adenocarcinoma outcome is a feature already present in patients' noninvolved lung tissue

Francesca Minnai, Sara Noci, Marco Chierici, Chiara Elisabetta Cotroneo, Barbara Bartolini, Matteo Incarbone, Davide Tosi, Giovanni Mattioni, Giuseppe Jurman, Tommaso A. Dragani, Francesca Colombo

Summary: Emerging evidence suggests that the prognosis of patients with lung adenocarcinoma can be determined from germline variants and transcript levels in nontumoral lung tissue. Gene expression data from noninvolved lung tissue of 483 lung adenocarcinoma patients were analyzed, and a signature of transcripts associated with lung adenocarcinoma outcome was identified. Pathway analysis indicated enrichment of ECM components. Genetic predisposition to lung adenocarcinoma outcome was found to be present in patients' noninvolved lung tissue.

CANCER SCIENCE (2023)

Article Oncology

Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness

Giancarla Bernardo, Valentino Le Noci, Emerenziana Ottaviano, Loris De Cecco, Chiara Camisaschi, Simone Guglielmetti, Martina Di Modica, Giorgio Gargari, Francesca Bianchi, Serena Indino, Patrizia Sartori, Elisa Borghi, Michele Sommariva, Elda Tagliabue, Tiziana Triulzi, Lucia Sfondrini

Summary: This study highlights the significant influence of mammary tumor microbiota on local immune status and the relevance of its treatment with antibiotics, in combination with breast cancer therapies.

CANCER LETTERS (2023)

Review Biology

Ovarian Cancer Radiosensitivity: What Have We Understood So Far?

Amelia Barcellini, Alexandra Charalampopoulou, Loris De Cecco, Andrei Fodor, Emanuela Rabaiotti, Giorgio Candotti, Simona Secondino, Angelica Facoetti, Laura Deborah Locati, Sandro Pignata, Ester Orlandi, Giorgia Mangili

Summary: Radiotherapy is increasingly being used in combination with surgery, chemotherapy, and novel drugs to treat ovarian cancer. This review aims to summarize the current understanding of the radiosensitivity and radioresistance of ovarian cancer, which is the deadliest gynecological cancer worldwide. Understanding the mechanisms of radiosensitivity and identifying potential biomarkers of radioresistance could be crucial in guiding clinical decision-making, considering the high rate of recurrence in and out of the radiotherapy fields, especially in the era of personalized oncology.

LIFE-BASEL (2023)

Article Oncology

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

Luca Forlani, Loris De Cecco, Vittorio Simeon, Biagio Paolini, Marina Bagnoli, Sabrina Chiara Cecere, Anna Spina, Eleonora Citeroni, Eliana Bignotti, Domenica Lorusso, Laura Arenare, Daniela Russo, Carmine De Angelis, Laura Ardighieri, Giosue Scognamiglio, Michele Del Sesto, Germana Tognon, Daniela Califano, Clorinda Schettino, Paolo Chiodini, Francesco Perrone, Delia Mezzanzanica, Sandro Pignata, Antonella Tomassetti

Summary: The membrane expression of EGFR can serve as a prognostic biomarker in ovarian cancer patients and is associated with the efficacy of anti-angiogenic therapy.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Correction Oncology

SELP Asp603Asn and severe thrombosis in COVID-19 males (vol 14, 123, 2021)

Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian, Maria Palmieri, Susanna Croci, Andrea M. M. Isidori, Simone Furini, Elisa Frullanti, Alessandra GEN-COVID Multictr Study, Alessandra Renieri, Francesca Mari

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Article Oncology

A pilot exome sequencing study suggests that germline variants influence methotrexate-induced toxicities in pediatric patients with localized osteosarcoma

Francesca Minnai, Sara Noci, Nunzia Mangano, Loris De Cecco, Cristina Meazza, Monica Terenziani, Maura Massimino, Francesca Colombo

Summary: In this exome-wide association study, gene sets significantly associated with neutropenia and hepatotoxicity induced by methotrexate were identified in pediatric osteosarcoma patients. However, further validation and functional characterization of these associations are needed in larger series, emphasizing the importance of investigating variants along the whole genome to identify potential pharmacogenes.

PEDIATRIC BLOOD & CANCER (2023)

Article Oncology

Lung Adenocarcinoma Diagnosed at a Younger Age Is Associated with Advanced Stage, Female Sex, and Ever-Smoker Status, in Patients Treated with Lung Resection

Tommaso A. Dragani, Thomas Muley, Marc A. Schneider, Sonja Kobinger, Martin Eichhorn, Hauke Winter, Hans Hoffmann, Mark Kriegsmann, Sara Noci, Matteo Incarbone, Davide Tosi, Sara Franzi, Francesca Colombo

Summary: This study examined the relationships between smoking habit, clinical stage, and sex with age at diagnosis of lung adenocarcinoma. The results showed that smoking, advanced stage, and female sex were associated with younger age at diagnosis. This study provides new insights into the clinical variables influencing age at diagnosis and opens up possibilities for further research on the genetic and molecular mechanisms responsible for these associations.

CANCERS (2023)

Review Biochemistry & Molecular Biology

Chios Mastic Gum: Chemical Profile and Pharmacological Properties in Inflammatory Bowel Disease: From the Past to the Future

Roberta Ottria, Ornella Xynomilakis, Silvana Casati, Ezio Abbiati, Giovanni Maconi, Pierangela Ciuffreda

Summary: This article provides a summary of the effects of P. lentiscus var. Chia gum on inflammatory bowel disease, discussing its chemical composition and pharmacological action. The review offers guidance for future research and highlights the possible bioactive components of mastic gum.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Environmental Sciences

The EU's Per- and Polyfluoroalkyl Substances (PFAS) Ban: A Case of Policy over Science

Francesca Spyrakis, Tommaso A. Dragani

Summary: The proposal by the European Chemicals Agency to ban over 12,000 per- and polyfluoroalkyl substances has sparked a debate about the potential consequences for the economy, industry, and the environment. A blanket ban may lead to unsafe alternative materials and unintended environmental consequences.

TOXICS (2023)

Letter Surgery

Peritoneal fluid COVID-19 testing in patients with a negative nasopharyngeal swab: prospective study

Armando G. Licata, Chiara M. Ciniselli, Luca Sorrentino, Arianna Micali, Maria Grazia Daidone, Marcello Guaglio, Manuela Gariboldi, Paolo Verderio, Loris De Cecco, Maurizio Cosimelli

BRITISH JOURNAL OF SURGERY (2023)

Meeting Abstract Oncology

miRNA and response to trastuzumab

Giulia Cosentino, Sara Pizzamiglio, Chiara M. Ciniselli, Loris De Cecco, Alessandra Cataldo, Ilaria Plantamura, Tiziana Triulzi, Sarra El-Abed, Yingbo Wang, Mohammed Bajji, Paolo Nuciforo, Jens Huober, Susan L. Ellard, David L. Rimm, Andrea Gombos, Mariagrazia Daidone, Paolo Verderio, Elda Tagliabue, Serena Di Cosimo, Marilena V. Iorio

CANCER RESEARCH (2022)

暂无数据